Currently, response prediction for targeted and immunotherapies is based on biomarkers for immunogenic tumor microenvironment (eg, programmed cell death ligand 1 [PD‐L1] expression) and mutational status (eg, EGFR). Here, CD274 is linked to neoplasm.